Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-26
2007-06-26
Chernyshev, Olga N. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S350000, C424S192100, C424S184100, C424S185100, C435S069100
Reexamination Certificate
active
10752041
ABSTRACT:
The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.
REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5278049 (1994-01-01), Baker et al.
patent: 5495001 (1996-02-01), McGrogan et al.
patent: 5700924 (1997-12-01), Braxton et al.
patent: 5955284 (1999-09-01), Braxton et al.
patent: 6008020 (1999-12-01), Hastings et al.
patent: 6191260 (2001-02-01), Hastings et al.
patent: 2226919 (1999-08-01), None
patent: WO 96/40922 (1996-12-01), None
patent: WO 98//16643 (1998-04-01), None
patent: WO 99/41381 (1999-08-01), None
patent: WO 00/53793 (2000-09-01), None
Berger, et al., “Structure of the mouse gene for the serine protease inhibitor neuroserpin (PI12),”Gene, 214:25-33 (1998).
Berkenpas, et al., “Molecular evolution of plasminogen activator inhibitor-1 functional stability,”The EMBO J.. 14(13);2969-2977 (1995).
Bjork, et al., “Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1and P14region of the putative reactive bond loop of the inhibitor,”J. Biol. Chem., 267(3):1976-1982 (1992).
Bjork, et al., “Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor,”J. Biol. Chem., 267(27):19047-19050 (1992).
Eitzman et al. “Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitort-1 in vitro,” J. Clin. Invest. 95:2416-2420 (1995).
Genbank Accession No. R12152 (1995).
Genbank Accession No. AA115876 (1996).
Genbank Accession No. AA164563 (1996).
Genbank Accession No. AA165401 (1996).
Genbank Accession No. F07041 (1995).
Genbank Accession No. H09005 (1995).
Genbank Accession No. H09572 (1995).
Genbank Accession No. N47859 (1996).
Genbank Accession No. R42394 (1995).
Genbank Accession No. R14666 (1995).
Genbank Accession No. N50314 (1996).
Genbank Accession No. R15085 (1995).
Genbank Accession No. N53887 (1996).
Hastings, et al., “Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival,”J. Biol. Chem., 272:33062-33067 (1997).
Hill, et al., “Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells,”Biochem. J.,345:595-601 (2000).
Hillier, et al., “Generation and analysis of 280,000 Human Expressed Sequence Tags,”Genome Research, 6:807-828 (1996).
Houenou, et al., “A serine protease inhibitor, protease nexin I, rescues motoneurons from naturally occurring and axotomy-induced cell death,”PNAS USA, 92:895-899 (1995).
Krueger, et al., “Expression of neuroserpin, and inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse,”Journal of Neuroscience, 17(23):8984-8996 (1997).
Kvassman, et al., “The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into β-sheet A,”J. Biol. Chem., 270(46):27942-27947 (1995).
Lawrence, et al., “Serpin reactive center ILoop mobility is required for inhibitor function but not for enzyme recognition,”J. Biol. Chem., 269(44):27657-27662 (1994).
Lawrence, et al., “Structure-function studies of the SERPIN plasminogen activator inhibitor type 1,”J. Biol. Chem., 265(33)20293-20301 (1990).
Lawrence, et al., “Molecular basis of thrombosis and hemostatsis,” edited by High & Roberts, publ.: Marcet Dekke, Inc., pp. 517-543 (1995).
Osterwalder, et al., “Neuroserpin, and axonally secreted serine protease inhibitor,”EMBO J., 15:2944-2953 (1996).
Osterwalder, et al., “The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin,”J. Biol. Chem., 273(4):2312-2321 (1998).
Reilly, et al., “Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects,”Blood Coagulation and Fibrinolysis, 5:73-81 (1994).
Schrimpf, et al., “Human neuroserpin (PI12): cDNA cloning and chromosomal localization to 3q26,”Genomics, 40:55-62 (1997).
Schultze, et al., “Structural transition of α1-antitrypsin by a peptide sequentially similar to β-strand s4A,”Eur. J. Biochem., 1994:51-56 (1990).
Wiegand, et al., “Cloning of the cDNA encoding human brain trypsinogen and characterization of its product,”Gene, 136:167-175 (Dec. 22, 1993).
Yepes, et al. ,“Neuroserpin protects neurons from excitotoxin-induced cell death,” [Abstract submitted] First Chianti Meeting, Apr. 27-May 1, 2001, Siena, Italy.
Yepes, et al., “Neuroserpin decreases stroke volume and inhibits apoptosis in an animal model of focal cerebral ischemia/reperfusion,” [Abstract submitted] 2ndInternational Symposium on the Structure and Biology of Serpins, Jun. 27-Jul. 1, 1999, Cambridge, UK.
Yepes, et al., “Neuroserpin, a brain associated tPA inhibitor, decreases stroke volume and inhibitors apoptosis in area of ischemic penumbra,” [Abstract submitted] XVIIth Congress of the International Society on Thrombosis and Haemostasis, Aug. 14-21, 1999, Washington, D.C.
Yepes, et al., “Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis,”Blood, 96:569-576 (2000).
Teschauer et al., “Primary structure of a porcine leukocyte serpin,”Eur. J. Biochem., 217:519-526 (1993).
Zhang et al., “Adjuvant Treatment With Neuroserpin Increases the Therapeutic Window for Tissue-Type Plasminogen Activator Administration in a Rat Model of Embolic Stroke,”Circulation, 106:740-745 (2002).
Coleman Timothy A.
Lawrence Daniel A.
Yepes Manuel
Chernyshev Olga N.
Human Genome Sciences Inc.
The Regents of the University of Michigan
LandOfFree
Brain-associated inhibitor of tissue-type plasminogen activator does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Brain-associated inhibitor of tissue-type plasminogen activator, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Brain-associated inhibitor of tissue-type plasminogen activator will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873997